Cryoneurolysis uses a probe to apply controlled cold to a selected peripheral nerve. The cold creates a temporary interruption in pain signaling while the nerve structure later recovers.
It is a pain-focused procedure. It does not restore cartilage, change alignment, or repair a knee implant.
Find cryoneurolysis programs Compare pain-targeted procedures
What is it used for?
One current FDA-cleared iovera system is indicated for relief of pain and symptoms associated with knee osteoarthritis for up to 90 days. Cryoneurolysis has also been studied around knee-replacement surgery and in other pain conditions, but the evidence and intended role are not identical across those settings.
A provider page should state whether a program uses cryoneurolysis for:
- Native-knee osteoarthritis.
- Short-term pain around knee replacement.
- Persistent pain after knee surgery.
- Another focal peripheral-nerve pain problem.
KneeLife does not infer one use from another.
What does the evidence show?
A multicenter sham-controlled trial reported improved knee pain and symptoms after treatment of the infrapatellar branch of the saphenous nerve, with benefit reported through 150 days in the studied group.
More recent systematic reviews generally find a signal of benefit, but emphasize the small number of trials, variation in technique and nerve targets, and low or very low certainty for some outcomes. FDA clearance confirms the device’s allowed indication and substantial equivalence; it does not mean cryoneurolysis has been proven superior to every alternative.
A fair summary is:
> Cryoneurolysis is a legitimate, minimally invasive pain option with randomized evidence, but the evidence base is smaller and less mature than its marketing may suggest.
How is it different from RFA?
| Feature | Cryoneurolysis | Radiofrequency ablation |
|---|---|---|
| Energy | Controlled cold | Heat or cooled radiofrequency energy |
| Target | Selected peripheral sensory nerve | Commonly selected genicular sensory branches |
| Intended effect | Temporary interruption of nerve signaling | Temporary denervation/pain-signal interruption |
| Implant | None | None |
| Evidence | Limited; includes sham-controlled OA trial | Broader knee-OA evidence, still heterogeneous |
| Duration | Varies; one FDA-cleared indication states up to 90 days | Varies; often discussed in months rather than days |
The procedures are not interchangeable. The targeted nerve, technique, diagnosis, and provider experience matter.
What a patient should clarify
- What exact nerve will be targeted?
- Is the treatment for OA, perioperative pain, or persistent postsurgical pain?
- What does the provider expect the treatment to change?
- What numbness, bruising, weakness, skin injury, or nerve symptoms can occur?
- How long might benefit last?
- What happens if the nerve cannot be located or the treatment does not help?
- Is insurance coverage established for this indication?
Potential advantages
- No implant remains in the body.
- Can be performed in an outpatient setting.
- Avoids systemic medication exposure.
- The nerve effect is intended to be temporary rather than permanent.
Important limitations
- It treats pain signaling, not the structural cause of arthritis.
- Benefit may be partial or short-lived.
- The best nerve target can differ among patients.
- Evidence for chronic pain after knee replacement is less established than evidence for native-knee OA or perioperative use.
- Provider availability and coverage can be difficult to determine.
Browse source-verified cryoneurolysis programs